Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients

Artificial Organs

Volumn 37, Issue 7, 2013, Pages

  Arsov, Stefan ^a   Trajceska, Lada ^a   van Oeveren, Wim ^b   Smit, Andries J ^b   Dzekova, Pavlina ^a   Stegmayr, Bernd ^c   Sikole, Aleksandar ^a   Rakhorst, Gerhard ^b   Graaff, Reindert ^b  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Advanced glycation end products; Cardiovascular disease; Heart type fatty acid binding protein; Hemodialysis; Mortality; Skin autofluorescence

Indexed keywords

CELL ADHESION; DIALYSIS; FATTY ACIDS; GLYCOSYLATION; HEMODIALYZERS;

ADVANCED GLYCATION END PRODUCTS; CARDIOVASCULAR DISEASE; FATTY ACID-BINDING PROTEINS; HAEMODIALYSIS; HEART-TYPE FATTY ACID; HEART-TYPE FATTY ACID BINDING PROTEIN; HEMODIALYSIS PATIENT; MORTALITY; PLASMA MARKERS; SKIN AUTOFLUORESCENCE;

ENZYMES;

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MYELOPEROXIDASE; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; AUTOFLUORESCENCE; BLOOD ANALYSIS; CARDIOVASCULAR MORTALITY; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SKIN;

EID: 84880255614     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12078     Document Type: Article

References (32)

1. U.S. Renal Data System U2. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008.
2. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008;3:505-521.
3. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005;16:1471-1485.
4. Meerwaldt R, Zeebregts CJ, Navis G, Hillebrands JL, Lefrandt JD, Smit AJ. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 2009;53:138-150.
5. Meerwaldt R, Graaff R, Oomen PH, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-1330.
6. Meerwaldt R, Hartog JW, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-3693.
7. Hartog JW, de Vries AP, Lutgers HL, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 2005;1043:299-307.
8. Matsumoto T, Tsurumoto T, Baba H, et al. Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods. Rheumatol Int 2007;28:157-160.
9. Arsov S, Graaff R, Morariu AM, et al. Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients? Nephrol Dial Transplant 2010;25:885-891.
10. American Diabetic Association. Revisions for the 2004 clinical practice recommendations. Diabetes Care 2004;27:s5-s10.
11. World Health Organization. International Classification of Disease and Related Health Problems 10th Revision. WHO/DIMDI, 2009.
12. Koetsier M, Lutgers HL, de Jong C, Links TP, Smit AJ, Graaff R. Reference values of skin autofluorescence. Diabetes Technol Ther 2010;12:399-403.
13. Mulder DJ, Water TV, Lutgers HL, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006;8:523-535.
14. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3. Clin J Am Soc Nephrol 2011;6:2356-2363.
15. Pawlak K, Pawlak D, Mysliwiec M. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. Clin Biochem 2007;40:81-85.
16. Dominguez-Rodriguez A, Abreu-Gonzalez P, Kaski JC. Diurnal variation of circulating myeloperoxidase levels in patients with ST-segment elevation myocardial infarction. Int J Cardiol 2010;144:407-409.
17. Sabry AA, Elbasyouni SR, Kalil AM, Abdel-Rahim M, Mohsen T, Sleem A. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus. Nephrology (Carlton) 2006;11:329-335.
18. Oktay B, Akbal E, Firat H, Ardic S, Akdemir R, Kizilgun M. Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome. Sleep Breath 2008;12:223-228.
19. Meerwaldt R, Lutgers HL, Links TP, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007;30:107-112.
20. Gerrits EG, Lutgers HL, Smeets GH, et al. Skin autofluorescence: a pronounced marker of mortality in hemodialysis patients. Nephron Extra 2012;2:184-191.
21. Dellas C, Puls M, Lankeit M, et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol 2010;55:2150-2157.
22. Lankeit M, Dellas C, Panzenbock A, et al. Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2008;31:1024-1029.
23. Viswanathan K, Kilcullen N, Morrell C, et al. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol 2010;55:2590-2598.
24. O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006;114:550-557.
25. McCann CJ, Glover BM, Menown IB, et al. Prognostic value of a multimarker approach for patients presenting to hospital with acute chest pain. Am J Cardiol 2009;103:22-28.
26. Niizeki T, Takeishi Y, Arimoto T, et al. Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ J 2008;72:109-114.
27. Haltern G, Peiniger S, Bufe A, Reiss G, Gulker H, Scheffold T. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol 2010;105:1-9.
28. Li CJ, Li JQ, Liang XF, et al. Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction. Acta Pharmacol Sin 2010;31:307-312.
29. Valle HA, Riesgo LG, Bel MS, Gonzalo FE, Sanchez MS, Oliva LI. Clinical assessment of heart-type fatty acid binding protein in early diagnosis of acute coronary syndrome. Eur J Emerg Med 2008;15:140-144.
30. Hofstra JM, Deegens JK, Steenbergen EJ, Wetzels JF. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy. Nephrol Dial Transplant 2008;23:3160-3165.
31. Morariu AM, Schuurs TA, Leuvenink HG, van Oeveren W, Rakhorst G, Ploeg RJ. Early events in kidney donation: progression of endothelial activation, oxidative stress and tubular injury after brain death. Am J Transplant 2008;8:933-941.
32. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009;4:1925-1931.